Table 2 Responses to treatment
From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Response | Efficacy population (n = 60) | KMT2Ar (n = 46) | Mutated NPM1 (n = 14) |
|---|---|---|---|
Overall response* | 32 (53%) | 27 (59%) | 5 (36%) |
Median time to first morphologic response (range), months | 0.95 (0.9–3.7) | 0.95 (0.9–3.7) | 0.99 (1.0–1.9) |
Best response* | |||
CR/CRh | 18 (30%) | 15 (33%) | 3 (21%) |
CR | 12 (20%) | 9 (20%) | 3 (21%) |
CRh | 6 (10%) | 6 (13%) | 0 |
Median time to CR or CRh (range), months | 1.9 (0.9–4.9) | 2.0 (0.9–4.9) | 1.9 (1.0–1.9) |
CRi | 0 | 0 | 0 |
CRp | 5 (8%) | 5 (11%) | 0 |
MLFS | 9 (15%) | 7 (15%) | 2 (14%) |
Partial remission | 0 | 0 | 0 |
No response | 19 (32%) | 12 (26%) | 7 (50) |
Progressive disease | 7 (12%) | 6 (13%) | 1 (7%) |
Missing | 2 (3%) | 1 (2%) | 1 (7%) |
MRD† neg. rate within CR/CRh | 14/18 (78%) | 11/15 (73%) | 3/3 (100%) |
Median time to MRD† neg. among patients with CR/CRh (range), months | 1.9 (0.9–4.9) | 1.9 (0.9–4.9) | 1.9 (1.0–2.8) |
